Zhang, Yajing <br/><br/>
An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.  [electronic resource] 

 -  Science China. Life sciences  Apr 2016 
 - 379-85 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1869-1889 
<br/><br/><label>Standard No.: </label>10.1007/s11427-016-5035-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antigens, CD19--genetics<br/>Biomarkers, Tumor--analysis<br/>C-Reactive Protein--immunology<br/>Clinical Trials, Phase I as Topic<br/>Female<br/>Humans<br/>Immunotherapy, Adoptive--methods<br/>Interferon-gamma--blood<br/>Interleukin-10--blood<br/>Interleukin-6--blood<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--immunology<br/>Receptors, Antigen, T-Cell--genetics<br/>Recombinant Fusion Proteins--genetics<br/>Remission Induction<br/>T-Lymphocytes--immunology<br/>Treatment Outcome